China Medical System Holdings stock analysis
Want to see HK:0867 full AI Analyst Report?
China Medical System Holdings (0867) Stock Price & Analysis
0867 Stock Chart & Stats
- Day’s Range
- HKD 10.21 - HKD 10.89
- 52-Week Range
- HKD 9.49 - HKD 15.52
- Previous Close
- HKD 10.60
- Volume
- N/A
- Average Volume (3M)
- 3.79M
- Market Cap
- HKD 25.71B
- Enterprise Value
- HKD 19.40B
- Total Cash (Recent Filing)
- HKD 5.75B
- Total Debt (Recent Filing)
- HKD 882.77M
- Price to Earnings (P/E)
- 14.5
- Beta
- 0.85
- Next Earnings
- Mar 16, 2027 (Est.)
- EPS Estimate
- 0.46
- Last Dividend Ex-Date
- Aug 28, 2026
- Dividend Yield
- 3.26%
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet
Very low leverage and steadily growing equity provide CMS with financial flexibility to sustain operations, pursue product commercialization, and absorb earnings volatility. This conservative capital structure reduces balance-sheet pressure and leaves more capacity for future investment or shareholder returns.
High Gross Margins
CMS continues to operate with high gross margins, indicating that its pharmaceutical commercialization model retains substantial value after product costs. Even with profitability pressure, an approximately 18% net margin supports internal funding, resilience, and continued investment in its portfolio and market access.
2025 Revenue Rebound
The sharp 2025 revenue rebound demonstrates that CMS retains the ability to restore top-line performance after a weaker period. While consistency remains a concern, renewed sales growth can improve operating leverage, support cash generation, and reinforce the company’s commercial platform over the coming quarters.
Bears Say
Long-Term Earnings Decline
The sustained reduction in net income since 2022 indicates that CMS’s earnings power has weakened materially, despite its high-margin model. Lower profit reduces funds available for portfolio expansion, limits the durability of shareholder returns, and makes future growth more dependent on successful execution.
Weaker Cash Generation
Deteriorating operating and free cash flow reduces CMS’s ability to fund growth, licensing activity, and distributions from internally generated resources. The sharp latest-year decline also signals lower cash resilience, making business performance more sensitive to further earnings weakness or working-capital demands.
Profitability Efficiency Pressure
The substantial decline in return on equity shows that CMS is generating less profit from its growing equity base than it did historically. Combined with compressed operating margins, this points to weaker capital efficiency and could constrain long-term compounding unless profitability improves.
China Medical System Holdings News
0867 FAQ
What was China Medical System Holdings’s price range in the past 12 months?
What is China Medical System Holdings’s market cap?
When is China Medical System Holdings’s upcoming earnings report date?
How were China Medical System Holdings’s earnings last quarter?
Is China Medical System Holdings overvalued?
Does China Medical System Holdings pay dividends?
What is China Medical System Holdings’s EPS estimate?
How many shares outstanding does China Medical System Holdings have?
What happened to China Medical System Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of China Medical System Holdings?
What is the TipRanks Smart Score and how is it calculated?
China Medical System Holdings Stock Smart Score
Company Description
China Medical System Holdings
Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Kong Lam
- Employees
- 6,415
- Website
- web.cms.net.cn/zh/home
- Address
- HK
China Medical System Holdings (0867) Earnings & Revenues
0867 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 2 | 10 |
| Technical Analysis | 4 | 2 | 4 |
| Moving Averages | 6 | 0 | 6 |











